Pulmocide
is an England-based biopharmaceutical company that researches and develops novel inhaled therapies for the treatment of chronic respiratory diseases... Read morePulmocide
is an England-based biopharmaceutical company that researches and develops novel inhaled therapies for the treatment of chronic respiratory diseases... Read more
Chairman & CEO
Daniel Burgess
News
Jan 11, 2026
Indian Pharma Post
Pulmocide: Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection
Jan 08, 2026
Clinical Trials Arena
Pulmocide: Pulmocide stops IPA trial after higher mortality rate in treated patients
Jan 10, 2025
Benzinga
Pulmocide: Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Apr 16, 2024
Clinical Trials Arena
Pulmocide: Pulmocide's inhaled antifungal shows promise in lung transplant patients
Apr 15, 2024
OINDPnews
Pulmocide: Pulmocide says that Phase 2 trial demonstrated safety and tolerability of inhaled opelconazole
Apr 15, 2024
StreetInsider
Press Release: Pulmocide : Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
Jan 03, 2024
GlobeNewswire
Press Release: Pulmocide : Pulmocide Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Oct 16, 2023
BioSpace
Pulmocide: Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole
Jun 09, 2023
BioCentury
Pulmocide: New CFO, commercial officer at Pulmocide
Jun 08, 2023
GlobalNewswire
Press Release: Pulmocide : Pulmocide Announces Expansion of Management Team
Pulmocide Competitors
1
2
3
4
5
6
7
8
9
10